This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LaRocco, M. T. Articles by Burgert, S. J. Search for Related Content PubMed PubMed Citation Articles by LaRocco, M. T. Articles by Burgert, S. J.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, Apr 1997, 277-297, Vol 10, No. 2
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation

MT LaRocco and SJ Burgert
Department of Pathology, St. Luke's Episcopal Hospital, Houston, TX 77225-0269, USA.

Over the past quarter century, tremendous technological advances have been made in bone marrow and solid organ transplantation. Despite these advances, an enduring problem for the transplant recipient is infection. As immunosuppressive regimens have become more systematic, it is apparent that different pathogens affect the transplant recipient at different time points in the posttransplantation course, since they are influenced by multiple intrinsic and extrinsic factors. An understanding of this evolving risk for infection is essential to the management of the patient following transplantation and is a key to the early diagnosis and treatment of infection. Likewise, diagnosis of infection is dependent upon the quality of laboratory support, and services provided by the clinical microbiology laboratory play an important role in all phases of clinical transplantation. These include the prescreening of donors and recipients for evidence of active or latent infection, the timely and accurate microbiologic evaluation of the transplant patient with suspected infection, and the surveillance of asymptomatic allograft recipients for infection. Expert services in bacteriology, mycology, parasitology, virology, and serology are needed and communication between the laboratory and the transplantation team is paramount for providing clinically relevant, cost-effective diagnostic testing.

This article has been cited by other articles:

• Zhang, L., Yan, K., Zhang, Y., Huang, R., Bian, J., Zheng, C., Sun, H., Chen, Z., Sun, N., An, R., Min, F., Zhao, W., Zhuo, Y., You, J., Song, Y., Yu, Z., Liu, Z., Yang, K., Gao, H., Dai, H., Zhang, X., Wang, J., Fu, C., Pei, G., Liu, J., Zhang, S., Goodfellow, M., Jiang, Y., Kuai, J., Zhou, G., Chen, X. (2007). High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc. Natl. Acad. Sci. USA 104: 4606-4611 [Abstract] [Full Text]  
• Lang, K. S., Recher, M., Navarini, A. A., Freigang, S., Harris, N. L., van den Broek, M., Odermatt, B., Hengartner, H., Zinkernagel, R. M. (2005). Requirement for Neutralizing Antibodies to Control Bone Marrow Transplantation-Associated Persistent Viral Infection and to Reduce Immunopathology. J. Immunol. 175: 5524-5531 [Abstract] [Full Text]  
• Rodier, M.-H., Imbert, C., Kauffmann-Lacroix, C., Daniault, G., Jacquemin, J.-L. (2003). Immunoglobulins G could prevent adherence of Candida albicans to polystyrene and extracellular matrix components. J Med Microbiol 52: 373-377 [Abstract] [Full Text]  
• Matsumoto, M., Ishida, K., Konagai, A., Maebashi, K., Asaoka, T. (2002). Strong Antifungal Activity of SS750, a New Triazole Derivative, Is Based on Its Selective Binding Affinity to Cytochrome P450 of Fungi. Antimicrob. Agents Chemother. 46: 308-314 [Abstract] [Full Text]